Q-omics provides the consensus-scored HARBI1 profile across patient tissues and cancer cell-line models. HARBI1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HARBI1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HARBI1 RNA expression shows 19,261 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where HARBI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HARBI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HARBI1 survival associations across molecular data types. HARBI1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HARBI1 RNA expression–survival associations across cancer types. High HARBI1 expression shows unfavorable associations in LIHC, KICH and ACC, but favorable associations in KIRC, LUAD and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HARBI1 RNA expression.
This table summarizes HARBI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HARBI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HARBI1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUAD, STAD and LUSC. The HNSC box plot shows higher HARBI1 RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p < 0.001).
This table shows molecular features associated with HARBI1 in patient tissues and cancer cell lines. In patient samples, HARBI1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HARBI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
